Umdlavuza wesibindi
Umdlavuza wesibindi uyisimila esinothe emithanjeni, futhi imithambo yegazi yesimila idlala indima ebaluleke kakhulu ekuthuthukiseni umdlavuza wesibindi. Ngakho-ke, ukwelashwa okuhlosiwe kwamanje komdlavuza wesibindi kwenziwa nge-anti-angiogenesis. I-Anti-angiogenesis therapy iyisu elibaluleke kakhulu ekusebenzeni komtholampilo komdlavuza wesibindi.
FINYELELA IZIVIVINYO EZIMBILI
Uhlolo lwe-REACH-2 lwenziwa ngesisekelo sesivivinyo se-REACH. Isazi saseShayina saseMelika uSolwazi Andrew X. Zhu waseMassachusetts Hospital esixhumene ne-Harvard University e-United States sisebenza njenge-PI yomhlaba wonke. Okwe umdlavuza wesibindi iziguli ezihlulekile ukwelapha i-Sorafenib, isiqhathaniso i-Ramucirumab sihlukile ku-placebo ekusebenzeni komugqa wesibili wokwelashwa, kodwa uhlolo aluzange luyifinyelele imiphumela elindelekile. Kodwa ukuhlaziya i-subgroup yayo kubonisa ukuthi iziguli ezine-AFP (alpha-fetoprotein) ezingaphezu kuka-400 ng / ml zingazuza ekwelashweni kwe-Ramucirumab. Ngakho-ke, uProfessor Zhu uhole uhlolo lwe-REACH-2 futhi wathola ukuthi i-Ramucirumab izuzisa iziguli kokubili esikhathini sokusinda esiphelele kanye nesikhathi sokusinda esingathuthuki uma kuqhathaniswa ne-placebo. Lokhu kuhlola kunokubaluleka kokwenza inkathi, futhi kufakazela futhi ukuthi ekwelashweni komugqa wesibili womdlavuza wesibindi, ukwelashwa kwe-anti-angiogenesis ngama-macromolecular monoclonal antibodies kungazuza izinzuzo zokusinda ezinenjongo emtholampilo.
Njengamanje, i-oxaliplatin ivunyelwe njengohlelo lokwelapha olujwayelekile kuwo womabili amazwe asekhaya naseYurophu. Emithini eqondiswe kwi-molecule encane, i-sorafenib ne-lenvatinib ingasetshenziswa ekwelapheni komugqa wokuqala, futhi i-regorafenib ne-carbotinib isetshenziselwa ukwelashwa komugqa wesibili. Ezidakamizwa ezinama-molecule amakhulu, i-Nivolumab ne-Ramucirumab zombili yizidakamizwa ezithi Khetha.
Ngaphezu kwalokho, iziguli eziningi ezinomdlavuza wesibindi zine-hepatitis, kanti isiguli esifanayo, isitho esifanayo ngesikhathi esifanayo, kunezifo ezimbili ezihluke ngokuphelele. Olunye uhlobo yisifo sesibindi esiyisisekelo, okuhlanganisa ukusha kwesibindi, kungakhathaliseki ukuthi isifo sokusha kwesibindi sohlobo lwe-viral, noma isifo sesibindi esidakayo, isibindi esinamafutha, i-cirrhosis, kungase kube khona ukusebenza kwesibindi okungavamile nezinye izinkinga. Isigaba sesibili umdlavuza wesibindi othuthuke kakhulu. Lezi zifo ezimbili zithintana futhi zakha umbuthano ononya. Ngakho-ke, kuyadingeka ukucabangela ngokufanele ukuxilongwa kanye nenqubo yokwelashwa, ukuvimbela ukulahlekelwa komunye nomunye. Eminyakeni yamuva nje, kuye kwakhuthazwa ukuthi ukwelashwa kwe-antiviral nokuvikela isibindi kwenziwe kanyekanye. Lena enye inqubekelaphambili eyenziwe ekwelapheni umdlavuza wesibindi.
